FMS - Dialysis stocks tumble in wake of Ozempic kidney failure study update
2023-10-11 09:24:05 ET
More on Baxter, DaVita, etc.
- Outset Medical Faces Regulatory Delays Amid Heavy Cash Burn (Rating Downgrade)
- DaVita: Continued Economic Hurdles, Market Expectations May Be Correct
- Dividend Challengers Review: Baxter International
- DaVita shares drop amid update on Ozempic kidney failure study
For further details see:
Dialysis stocks tumble in wake of Ozempic kidney failure study update